Gastrointestinal Nematodes in Sheep: Anthelmintic Treatment Strategies and Resistance Management

Introduction

Gastrointestinal nematode (GIN) infections are a major constraint to sheep production globally, causing subclinical production losses, clinical disease, and mortality in lambs and periparturient ewes [1]. The principal genera involved are Haemonchus contortus (barber’s pole worm), Teladorsagia circumcincta (brown stomach worm), and Trichostrongylus spp. (including T. colubriformis and T. axei), with Nematodirus battus and Cooperia curticei also contributing in specific epidemiological contexts [1, 2]. The heavy reliance on anthelmintic drugs has led to widespread resistance, compromising sheep worms treatment efficacy and necessitating integrated management approaches [3]. This article reviews the biology, clinical impact, diagnosis, anthelmintic pharmacology, resistance mechanisms, and evidence-based control strategies for GIN in sheep.

Major Nematode Genera and Pathophysiology

Haemonchus contortus

Haemonchus contortus is a blood‑feeding abomasal nematode. Adult females are up to 30 mm long and produce large numbers of eggs [1, 2]. Pathogenesis is driven by blood loss: each worm consumes approximately 0.05 mL of blood daily, leading to anemia, hypoproteinemia, and submandibular edema (bottle jaw) in heavy infections [2, 4]. Periparturient ewes and weaned lambs are most susceptible [1, 4].

Teladorsagia circumcincta

Teladorsagia circumcincta inhabits the abomasum and causes type I and type II ostertagiosis in temperate regions [2, 5]. The emergence of inhibited larvae causes mucosal damage, protein‑losing enteropathy, diarrhea, and weight loss [2, 5]. Immunity develops slowly, and susceptibility persists in lambs and yearlings [5].

Trichostrongylus spp.

Trichostrongylus colubriformis (bankrupt worm) and T. axei (hairworm) are small intestinal and abomasal parasites, respectively [1, 2]. They cause enteritis, villous atrophy, and malabsorption, leading to ill thrift, diarrhea, and reduced weight gain [1, 2].

Clinical Signs

Clinical signs vary with worm burden, host immunity, and nutritional plane. Common manifestations include:

• Poor growth and reduced feed conversion efficiency in lambs [1, 4].
• Anemia, pale mucous membranes, and bottle jaw (H. contortus) [2, 4].
• Diarrhea or soft feces, especially in trichostrongylosis [1, 2].
• Rough fleece, depression, and submandibular edema [2].
• Periparturient rise in fecal egg counts (FEC) in ewes, leading to pasture contamination [1, 6].

In acute haemonchosis, death may occur without premonitory signs in heavily parasitized lambs [2, 4].

Diagnosis

Fecal Egg Count (FEC)

The cornerstone of GIN diagnosis is the quantitative fecal egg count using a modified McMaster technique or a flotation method with a sensitivity of 15–50 eggs per gram (epg) [1, 7]. FEC alone does not distinguish between genera, but larval culture and identification are used for speciation [1, 7]. Composite FEC samples from groups of 10–15 animals cost‑effectively monitor flock infection levels [6, 7].

Additional Diagnostic Tools

• FAMACHA scoring: a clinical anemia guide for selective treatment of H. contortus [4].
• Disssection and worm counts at necropsy for quantification [1].
• Serum pepsinogen and gastrin assays for abomasal damage, particularly T. circumcincta [2, 5].
• Molecular diagnostics (PCR) for species identification and resistance allele detection [8].

Anthelmintic Drug Classes

Benzimidazoles (BZ)

Benzimidazoles (e.g., albendazole, fenbendazole, oxfendazole) bind to β‑tubulin, disrupting microtubule formation [1]. Resistance is mediated by single nucleotide polymorphisms (SNPs) at codons 167, 198, and 200 in the β‑tubulin isotype 1 gene, reducing drug binding affinity [3, 8].

Macrocyclic Lactones (ML)

Macrocyclic lactones (ivermectin, abamectin, moxidectin) potentiate glutamate‑gated chloride channels, causing flaccid paralysis of the parasite [1]. Moxidectin is more lipophilic, persisting longer in tissues [1]. Resistance involves P‑glycoprotein efflux pumps and target‑site mutations in glutamate‑gated chloride channel subunits [3, 8].

Levamisole (LEV)

Levamisole is a nicotinic acetylcholine receptor agonist, causing sustained spastic paralysis [1]. Resistance is less well characterized but is associated with altered acetylcholine receptor expression [3, 9].

Monepantel

Monepantel is a member of the amino‑acetonitrile derivative (AAD) class, acting on a specific nicotinic acetylcholine receptor (Hco‑Mptl‑1) not present in mammals [1, 10]. It retains efficacy against BZ‑, ML‑, and LEV‑resistant populations [10]. Resistance has emerged in some regions, associated with mutations in the deg‑3‑like receptor [10].

Other Classes

Closantel is a salicylanilide used against Haemonchus, but it is not licensed for sheep in all jurisdictions [1]. Phoxim is an organophosphate used in combinations, but resistance is becoming more prevalent [3].

Anthelmintic Resistance: Mechanisms and Testing

Resistance is a heritable reduction in drug efficacy. Resistance mechanisms include target‑site mutations, enhanced drug efflux, and metabolic detoxification [3, 8]. Prevalence surveys across sheep‑producing regions show that resistance to BZ and ML is common, frequently exceeding 80 % of flocks for Haemonchus and Teladorsagia [3, 8]. Triple‑class resistance (BZ, ML, LEV) is increasingly reported [3, 9].

Resistance Testing

• Fecal egg count reduction test (FECRT): the gold standard field test. A reduction of <95 % in FEC or a lower 95 % confidence interval <90 % indicates resistance [1, 7].
• Molecular assays: real‑time PCR for BZ‑resistance SNPs and allele‑specific PCR for monepantel resistance [8].
• Egg hatch assay (for BZ) and larval development assay (for ML and LEV) are used in specialized laboratories [1, 7].

Integrated Control Strategies

The goal is to reduce selection pressure for resistance while maintaining effective worm control. The following table summarizes key interventions:

Decision Workflow for Anthelmintic Treatment

The Mermaid diagram below illustrates a clinical decision‑making process for sheep worms treatment integrating FEC, FAMACHA, and resistance history.

flowchart TD
    A[Flock enters risk period: post-weaning or periparturient], > B{Perform FEC & FAMACHA}
    B, >|FEC > 250 epg or FAMACHA 4-5| C[Calculate refugia level]
    C, > D{Resistance risk?}
    D, >|Low: First-time use of effective drug| E[Apply TST: treat only high-risk animals]
    D, >|High: Known resistance to BZ/ML| F[Use combination therapy: e.g., monepantel + levamisole]
    E, > G[Post-treatment FECRT after 10-14 days]
    F, > G
    G, >|Reduction < 95%| H[Confirm resistance and adjust strategy]
    G, >|Reduction ≥ 95%| I[Rotate drug class for next treatment cycle]
    H, > J[Implement quarantine drench and pasture rest]
    I, > K[Monitor FEC periodically per season]

Conclusion

Gastrointestinal nematodes remain a leading parasite challenge in sheep flocks worldwide. Effective management requires accurate diagnosis through FEC and FAMACHA, appropriate drug selection based on resistance profiles, and integration of non‑chemical strategies. The Gastrointestinal Nematodes in Sheep: Anthelmintic Resistance article provides further details on resistance mechanisms. For breed‑specific considerations, see Sheep Parasite Resistance: Anthelmintic Strategies and Breed-Specific Considerations. The veterinarian’s role in designing flock‑specific protocols is crucial to preserve anthelmintic efficacy and sustain sheep production.

References

[1] Taylor MA, Coop RL, Wall RL. Veterinary Parasitology. 4th ed. Chichester: Wiley-Blackwell; 2016.

[2] Urquhart GM, Armour J, Duncan JL, Dunn AM, Jennings FW. Veterinary Parasitology. 2nd ed. Oxford: Blackwell Science; 1996.

[3] Kaplan RM. Drug resistance in nematodes of veterinary importance: a status report. Trends in Parasitology. 2004;20(10):477–481.

[4] van Wyk JA, Bath GF. The FAMACHA system for managing haemonchosis in sheep and goats by clinically identifying individual animals for treatment. Veterinary Research. 2002;33(5):509–529.

[5] Fox MT. Pathophysiology of ostertagiosis. Veterinary Parasitology. 1993;46(1-4):73–82.

[6] Besier RB, Love SCJ, Habel J, Kopp SR, Jacobson CL. Managing anthelmintic resistance in sheep: a review. Australian Veterinary Journal. 2016;94(5):143–150.

[7] Coles GC, Jackson F, Pomroy WE, et al. The detection of anthelmintic resistance in nematodes of veterinary importance. Veterinary Parasitology. 2006;136(3-4):167–185.

[8] Beech RN, Skuce P, Bartley DJ, Martin RJ, Prichard RK, Gilleard JS. Anthelmintic resistance: markers for resistance, or susceptibility? Parasitology. 2011;138(2):160–174.

[9] Sutherland IA, Leathwick DM. Anthelmintic resistance in nematode parasites of sheep: learning from the New Zealand experience. New Zealand Veterinary Journal. 2011;59(4):190–200.

[10] Kaminsky R, Ducray P, Jung M, et al. A new class of anthelmintics effective against drug-resistant nematodes. Nature. 2008;452(7184):176–180. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.